bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate

10:30 EDT 14 Jun 2014 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
First two patients in the HGB-205 Study achieved transfusion independence within two weeks of an autologous transplant with bluebird’s lentiviral gene therapy bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company com...

Other Sources for this Article

Investor Relations:
bluebird bio, Inc.
Richard E. T. Smith, Ph.D., 339-499-9382
or
Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

NEXT ARTICLE

More From BioPortfolio on "bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Transplantation
Latest News Clinical Trials Research Drugs Reports Corporate
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Bioinformatics
Latest News Clinical Trials Research Drugs Reports Corporate
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Advertisement

Searches Linking to this Story